Compile Data Set for Download or QSAR
Report error Found 324 Enz. Inhib. hit(s) with all data for entry = 79
TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161400(US9682976, 77 | US9682976, 221 | US9682976, 186)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161737(US9682976, 182)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161765(US9682976, 203)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161764(US9682976, 202)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161762(US9682976, 220 | US9682976, 200)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161747(US9682976, 219 | BDBM161772 | US9682976, 189)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161769(US9682976, 207)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161768(US9682976, 206)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161767(US9682976, 205)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161762(US9682976, 220 | US9682976, 200)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161777(US9682976, 218 | US9682976, 224 | US9682976, 215)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161777(US9682976, 218 | US9682976, 224 | US9682976, 215)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161777(US9682976, 218 | US9682976, 224 | US9682976, 215)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161785(US9682976, 223)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161400(US9682976, 77 | US9682976, 221 | US9682976, 186)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161798(US9682976, 236)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161797(US9682976, 235)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161805(US9682976, 242)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM168227(US9682976, 240)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161799(US9682976, 237)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161818(US9682976, 255)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161808(US9682976, 249)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM160830(US9682976, 2)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161825(US9682976, 262)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161824(US9682976, 261)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161829(US9682976, 271 | US9682976, 266)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161829(US9682976, 271 | US9682976, 266)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161844(US9682976, 279 | US9682976, 278)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161844(US9682976, 279 | US9682976, 278)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161048(US9682976, 17)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM160848(US9682976, 16)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161842(US9682976, 276)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM160845(US9682976, 14)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161837(US9682976, 274 | US9682976, 273)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM160843(US9682976, 13)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161837(US9682976, 274 | US9682976, 273)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161074(US9682976, 28)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161852(US9682976, 284)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161069(US9682976, 23)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161850(US9682976, 282)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161848(US9682976, 281)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161857(US9682976, 289)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161873(US9682976, 301)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161100(US9682976, 40)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161161(US9682976, 50 | US9682976, 47)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161163(US9682976, 49)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161162(US9682976, 48)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161161(US9682976, 50 | US9682976, 47)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161897(US9682976, 317 | US9682976, 316)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

TargetInterleukin-2(Human)
Rigel Pharmaceuticals

US Patent
LigandPNGBDBM161170(US9682976, 56)
Affinity DataEC50: <100nMAssay Description:Primary T cell stimulation and IL2 ELISA: Human primary T cells (100,000 cells per well) were pre-incubated with or without test compound in Yssel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/14/2018
Entry Details
US Patent

Displayed 1 to 50 (of 324 total ) | Next | Last >>
Jump to: